R&D Trends

Report: Higher M&A activity and investor cash expected in 2017

Friday, December 9, 2016

Despite the uncertainty that loomed over the pharma and biotech sectors with unexpected outcomes from both the U.S. presidential election and U.K.’s vote to leave the EU, 2017 may bring renewed energy to the industry with potential for more corporate activity and cash flow. According to EP Vantage, the editorial branch of the market intelligence firm Evaluate, the Trump victory may lead to a slew of business-friendly initiatives, based on the predicted lessening of political scrutiny towards drug pricing. The report shows that although the issue of drug pricing is not going away, 2017 will start with a flush of new confidence for investors, and a possible uptick in mergers and acquisitions.

[Read More]

NovogeneAIT, GIS to establish genome sequencing center in Singapore

Friday, December 9, 2016

Novogene, a commercial provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise; AITbiotech, a Singapore biotechnology company; and the Genome Institute of Singapore (GIS) have announced that NovogeneAIT Genomics Singapore (NovogeneAIT) a new joint venture between Novogene and AITbiotech will establish a joint whole genome sequencing (WGS) center at Biopolis, Singapore.

[Read More]

Report: Global drug market will hit $1.5T in 2021

Friday, December 9, 2016

Total spending on medicines is forecast to reach $1.5 trillion by 2021, up 33% from 2016 levels, even as annual growth moderates from the record pace set in 2014 and 2015, according to new research released by the QuintilesIMS Institute. While historically large numbers of high-quality new medicines will emerge from the R&D pipeline in the next five years, pricing and market access pressures, lower volume growth in pharmerging markets and greater savings from patent expiries will contribute to the lower rate of growth.

[Read More]

Report: Vast swathes of human biology untouched by drug discovery programs

Monday, December 5, 2016

Scientists have created a map of all 1,578 licensed drugs and their mechanisms of action—as a means of identifying ‘uncharted waters’ in the search for future treatments. Their analysis of drugs licensed through the FDA reveals that 667 separate proteins in the human body have had drugs developed against them—just an estimated 3.5% of the 20,000 human proteins.

[Read More]